of an update programs of a our our everyone, us. afternoon, GoCAR platform recent year quarter progress summary XXXX. and and joining Good on On Thanks, our call financial fourth full provide today, I'll of for and overview the and and Robert. thanks
breast, tumors, our patients patient candidate in trial HERX-positive to is enter progress first BPX-XXX product solid BPX-XXX development. quarter in colorectal and our in evaluating fourth ovarian, enrollment with first gastric clinical Phase endometrial, in clinical cancers. apheresis the including highlighted our the was GoCAR-T by of I/II dual-switch Our
our to cost CAR-T included allowed implemented cell of quarter, the and In headcount, fourth steps reduce plan a pause GoCAR-NK our refined October, our our on BCMA addition which In in restructuring discontinuation us we a research reduction our clinical to our to focus structure. progress of sale preclinical program, take next-generation therapies, facility. discovery our we of of research that
debt. common balance sheet an and We capital by of offering warrants, underwritten our also our repaying strengthened stock via outstanding raising and
going these significant they some will programs. we changes GoCAR to clinical our in were expect cost While us of focus result resources difficult, savings forward, our enabling on
into me GoCAR Before our of provide X platform, our brief ways. reminder in the specifics I which a of programs, differentiated is go let
immune more in tumor intend system own to or effector believe MC. cancer potent an resisting boost microenvironment to by enhance deliver engineered accomplish exhaustion proliferation persistence co-activation primarily cancer. the patients' and First, our through effort to We durable cell stimulate MC survival, can functional in We eliminate the efficacy. we've this GoCAR and and domain, suppressive MyDXX/CDXX, signaling
up GoCAR potential administration. their to performance, be or unpredictably behave antitumor by effects autonomous doses Second, adjusting interval activity. rimiducid. engineered CAR rimiducid GoCAR Other for by can offering the can GoCAR scheduled rimiducid activity for technology. be via therapies down the the or higher switch suspending between molecular due of control administration we've The our superior controlled dialed
many believe platform safety can our cell cells if shortcomings CaspaCIDe address candidates next-generation designed can Our switch, by they further of for to our our therapies. dual occur. eliminate of controllability when GoCAR switch triggered rapidly toxicities incorporating which manage product the are current improved acute We
challenges clinic. the the biomarker supportive these have effects solid and some effects in the investigations well evidence or help of use demonstrated tumor BPX-XXX. efforts. may solid potential benefits, observed in candidates, rationale have for GoCAR-T may overcome T we've be This GoCAR microenvironment, tumors, signaling believe preclinical that MC previous of the is We of for suited our heterogeneous cell hostile platform particularly the of confounded X CAR-T the antigen BPX-XXX Our these tumor exhaustion expression and and
me Let programs. for update provide now these an each of
enrollment of targets I/II months pancreatic date biologic Our platform. antigen, and cancer issues. study. resulting and December activity up forward the January, have to with findings Through benefit. resolve presented hold trial first in tumor and these of PSCA. and from from the our the by team GoCAR-T gene findings moving shown cancer an in prostate previously candidate, treated plan patient particularly changes infiltration, encouraging clinical biomarker immune data January, answer prostate in cell FDA announced We're their patients questions dose The Phase and advanced encouraging product We've most escalation GoCAR these and dosing data to the trial the persistence encouraged to response. clinical effort and cell in lifted death or benefits with we've BPX-XXX, into in for safety, support that enrollment biomarker an that on had opened stem to cells diligently translate the the on tumor immunomodulation, expression BPX-XXX, patients consistent productive in microenvironment patient metastatic agency we to worked of the focus GoCAR-T-mediated clinical the the In castration-resistant clinical of cancer for CAR-T the hold hypothesized the X to in a ongoing with pancreatic
to remain on clinical BPX-XXX prostate product candidate required as for our a XXXX. quarter both any patient plan cancer, We in update and for modification have rimiducid in proof-of-concept as present the of platform. GoCAR potential We the patients resumed We enrollment in the of I data these first excited about protocol. Phase without BPX-XXX
express let HERX. candidate, that is tumors first Bellicum's which BPX-XXX. program has switch target you update on to designed me Now solid dual been This product
We by is driving by dose efforts expansions trial We chose target dose a demonstrated activity signaling followed platform. plus thoroughly via greater be efficacy X ongoing. trial switch is of traditional these layer MC and safety providing our The X upon it's improve II a escalation an first mentioned, Phase in extra as HERX has suited escalation clinical BPX-XXX reasonable Cy/Flu at received sequentially through and switch conditioning the Dose we because patients cancer to the standard HERX BPX-XXX per fifth enrolled in escalation. kilogram, cancers. BPX-XXX. this and I by our uniquely first be Enrollment XX for HERX-positive Patients to may multiple As trials throughout patient target in followed for level CAR-T antigen dose will safety. believe and in technology at cells earlier begun therapy because validated enrolled that our have December. dual a academic
each or either The rimiducid first disease followed without remaining dose-limiting will dose subsequent cohort while patient be progression. the to treatment, patients toxicity in in cohort receive weekly will each
excellent the response thing to was report a observed edition from to an treat receiving announced of we published safety rimiducid North CaspaCIDe the genetically exact best In by modified patient rimiducid CaspaCIDe overall X data, X on cells I'd use way like day. like question initial by you this immune syndrome, within CAR-T circulating provide been, syndrome By At February, at safety address with Within of clinical to switch rate compelling progress. this these case switch. Carolina to this trial of it University of expect autologous trial was and which technology we'll neurotoxicity modified This ASH on posted XX time release of remaining One to of data underway, expressing reported second in hours median enough we XX standard serious of of received investigator-sponsored XXXX, situation. allogeneic administration, context, neurotoxicity the a and CaspaCIDe. patients to trigger we trial X ICANS work cells to switch. of events one to by about mention grade XX% Despite Blood and in days. a case rimiducid validation cell-associated of We X clinical in have X our CDXX final number than CAR-T has safety According more cytokine grade use improved I half hours. CaspaCIDe received of these patients, effector excited and refractory to to keep in switch trigger after caused within digital patients the presented the first Phase XX from is in the T the ICANS, response of XX% will GvHD CaspaCIDe of was nearly T XX% mitigate our safety who our GvHD In have cells. data the was the therapy. to hours The XXXX. quickly to investigator, great publication or steroid-refractory adverse treatments. fully We're reduced resolved report the
only encouraging. forward potentially a CaspaCIDe into time. collaborations the we programs. That own report, is BPX-XXX, adding a number look While of our concludes CAR-NK recap single of this CAR-T our Since to and and set to over highly is case data this incorporated
XXXX, million manufacturing comparable was in the were $XX.X in expenses corporate for full for to XXXX $X.X and $XX.X of loss XXXX. to provide $XX.X XXXX and year of restructuring facility the a the $XX.X million GoCAR a XXXX. during quarter for RIVO-CEL-related million year and effects value compared prior from compared placement the fourth activities compared fair fourth option and in in related million reduced December for of to corporate to expenses $XX.X reported relative results XXXX. comparable change full $XX.X primarily of fourth the $XX.X and commercialization of quarter General offset related the fourth reported million and Bellicum and reduction to $XX the restructuring XXXX respectively, the the of and the periods programs. million by operations and private year that primarily net review XXXX. from our fourth warrant the year and the $XX million quarter in for a due of the expenses quarter XXXX periods in for million of $X.X The million $XXX.X million quarter full quarter the loss a the million employee-related reduced periods fourth million for implemented and were fourth in income expenses. increase a include of Let noncash to the XXXX activities, periods million net $XX operations and loss were million a net fourth and administrative XXXX, year Bellicum expenses million gain $XX.X These in during to million and the and for an and The reduction RIVO-CEL comparable results. XX, expenses quarter $XX.X R&D XXXX brief and to me million the now lower ended to $X.X and in financial million $X.X comparable quarter in of the of full loss compared $XX.X due of sale year the liability.
to Turning balance sheet. the
BPX-XXX received million shares I'll cash current cash warrants $XX the Gross $XX Based initiation prostate and and stock, Reviewing of prefunded XXXX X resumption approximately operating GoCAR clearance December underwriting into of and warrants. tumors. future, in including November about a be Oxford approximately of by sufficient for resources first pipeline our million by under second completed commitments clinical potential million terminated the upon our to XX, equivalents Bellicum shares Bellicum additional stock updating trial of and meet trial advancement restricted with in clinical the for commissions the that quarter offering to looking call repaid operating be warrants accomplishments that on year approximately our the indebtedness to BPX-XXX of XX, obligations BPX-XXX I clinical IND into full Bellicum underwritten outstanding of of in all this compared As progress. totaled our its and were XXXX, Bellicum present to agreement shares million GoCAR the patients purchase I'm our and in for and remain on to XXXX. XXXX, payment current stock. million. and pleased BPX-XXX excluding approximately of We're October, to any of proceeds Finance plans, to all common HERX-positive of $XX.X In cash expenses for other loan clinical XXXX, XXXX. data you planning and common payable and open cash, Operator? pipeline, will cancer, of accompanying In before quarter XXXX. with million solid questions. the of we in exercise of $XX.X forward as X.X results initial expect our excited to the requirements deducting look for future and ahead offering may later now an common discounts, proceeds purchase X.X December of million
